This study is currently not recruiting participants.

A Phase 1B Study of the Safety and Tolerability of INB039110 in Combination with Gemcitabine and nab-Paclitaxel in Subjects with Advanced Solid Tumors

Investigating the Safety of an Investigational Medication with Chemotherapy

Not Recruiting
18 years - 100 years
All
Phase N/A
1 Location

Brief description of study.

The purpose of this study is to find out if the drug INCB039110 is safe and tolerable in combination with a chemotherapy medicine called gemcitabine and another chemotherapy medicine called nab-paclitaxel.

Detailed description of study

The purpose of this study is to test the hypothesis that INCB039110 can be administered safely in combination with gemcitabine and nab-paclitaxel in subjects with advanced or metastatic cancer.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Advanced Solid Tumor
  • Age: 18 years - 100 years
  • Gender: All

This study investigates the safety and tolerability of an investigational medication when used with chemotherapy medicines gemcitabine and nab-paclitaxel. The purpose of this study is to determine if the investigational medication can be safely combined with these chemotherapy treatments in individuals with advanced or metastatic cancer.

Participants will receive the investigational medication along with gemcitabine and nab-paclitaxel. The study will monitor the safety and any side effects that occur when these treatments are used together.

  • Who can participate: Individuals with advanced or metastatic cancer may be eligible to participate. There are no specific age restrictions mentioned.
  • Study details: Participants will receive an investigational medication along with two chemotherapy medicines. The study aims to monitor the safety of this combination.
Updated on 19 Feb 2024. Study ID: 1306011660

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team